Actively Recruiting
Clinical and Molecular Epidemiology of Myeloproliferative Neoplasms (MPNs) Patient Registry
Led by University Health Network, Toronto · Updated on 2024-08-27
5000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are collecting clinical and molecular information from patients diagnosed with various types of myeloproliferative neoplasms (MPNs), a group of rare blood cancers where bone marrow cells develop abnormally. This observational registry aims to better understand these diseases by gathering data over time to help improve patient treatment and outcomes. It will also serve as a resource for future studies related to MPNs. The registry collects information from patients diagnosed with MPNs such as atypical chronic myeloid leukemia, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, essential thrombocythemia, mastocytosis, primary myelofibrosis, and others. Both past and ongoing clinical data, molecular profiles, treatment details, complications, symptom assessments, and survival outcomes are gathered at different points during the disease course up to 10 years. Participants provide written consent to have their clinical information collected and stored in a database. Data collected includes disease characteristics, treatment types, blood tests, genetic testing, symptom questionnaires, and complications from treatments or disease progression. Researchers review survival status and disease changes annually or when the disease transforms, with follow-up continuing for up to 10 years.
CONDITIONS
Brief Title
Myeloproliferative Neoplasms (MPNs) Patient Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of one of the following myeloproliferative neoplasms (MPNs): atypical chronic myeloid leukemia (aCML), chronic eosinophilic leukemia-not otherwise specified (CEL, NOS), chronic myelomonocytic leukemia (CMML), chronic neutrophilic leukemia (CNL), essential thrombocythemia (ET), juvenile myelomonocytic leukemia (JMML), mastocytosis, MPN unclassifiable, MPN/myelodysplastic syndrome unclassifiable (MPN/MDS unclassifiable), primary myelofibrosis (PMF), post-essential thrombocythemia myelofibrosis (post-ET MF), post-polycythemia vera myelofibrosis (post-PV MF), or refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T)
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 years
Participants with a diagnosis of myeloproliferative neoplasms (MPNs) are observed over time to collect clinical information, molecular profiling data, symptom assessments, and survival outcomes.
Annual visits or visits at the time of disease transformation
Trial Site Locations
Total: 1 location
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 1Z5
Actively Recruiting
Research Team
V
Vikas Gupta, MD
J
Jaime O. Claudio, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here